Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aldebaran, formerly known as SoftBank Robotics Europe, is a pioneer in the development of humanoid robotics with a strong focus on healthcare, therapy, and social assistance. The company's flagship robots, NAO and Pepper, are utilized globally as therapeutic tools for children with neurodevelopmental disorders, such as autism, and as cognitive companions for elderly patients with dementia. Their Romeo project specifically targets the development of larger humanoid robots capable of providing physical assistance to individuals with reduced autonomy. Now a subsidiary of United Robotics Group, Aldebaran continues to advance its 'Robotics for Good' initiative, integrating AI and social robotics into clinical and home-care environments. The company's platforms are widely adopted by researchers and healthcare providers to improve patient engagement and support rehabilitation efforts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aldebaran Robotics.